Literature DB >> 24301757

Analysis of BCR/ABL transcripts in healthy individuals.

J A Boquett1, J R P Alves, C E C de Oliveira.   

Abstract

The chimeric oncogene BCR/ABL, which is the product of reciprocal translocation between chromosomes 9 and 22, is a known molecular marker of chronic myeloid leukemia (CML), and is related to the major factors involved in leukemogenesis. Some previous studies have also reported the presence of this oncogene in peripheral blood cells of healthy individuals. In this study, we investigated the presence of BCR/ABL transcripts in peripheral blood of individuals aged 40 years or more without symptoms of CML. The presence of BCR/ABL transcripts was observed in 2 of the 30 individuals analyzed. The genesis of BCR/ABL transcripts and its presence in healthy individuals are topics of ongoing debate. The risks and biological implications of the presence of BCR/ABL transcripts in healthy individuals are challenging issues that remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24301757     DOI: 10.4238/2013.October.24.8

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  11 in total

Review 1.  Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.

Authors:  Michele Baccarani; Robert Peter Gale
Journal:  Leukemia       Date:  2021-05-17       Impact factor: 11.528

Review 2.  The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

Authors:  Naranie Shanmuganathan; Susan Branford
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 3.  Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia.

Authors:  Theodora S Ross; Victoria E Mgbemena
Journal:  Mol Cell Oncol       Date:  2014-10-29

4.  Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome.

Authors:  Katarzyna Iżykowska; Grzegorz K Przybylski; Claudia Gand; Floriane C Braun; Piotr Grabarczyk; Andreas W Kuss; Karolina Olek-Hrab; Armando N Bastidas Torres; Maarten H Vermeer; Willem H Zoutman; Cornelis P Tensen; Christian A Schmidt
Journal:  Oncotarget       Date:  2017-06-13

Review 5.  Chronic myeloid leukemia stem cells.

Authors:  Mohammad Houshmand; Giorgia Simonetti; Paola Circosta; Valentina Gaidano; Alessandro Cignetti; Giovanni Martinelli; Giuseppe Saglio; Robert Peter Gale
Journal:  Leukemia       Date:  2019-05-24       Impact factor: 11.528

6.  Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia.

Authors:  Simona Bernardi; Chiara Foroni; Camilla Zanaglio; Federica Re; Nicola Polverelli; Alessandro Turra; Enrico Morello; Mirko Farina; Federica Cattina; Lisa Gandolfi; Tatiana Zollner; Eugenia Accorsi Buttini; Michele Malagola; Domenico Russo
Journal:  Int J Mol Med       Date:  2019-10-14       Impact factor: 4.101

Review 7.  Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice.

Authors:  Camille C B Kockerols; Peter J M Valk; Mark-David Levin; Niels Pallisgaard; Jan J Cornelissen; Peter E Westerweel
Journal:  Hemasphere       Date:  2020-11-24

Review 8.  Personalized Cancer Risk Assessments for Space Radiation Exposures.

Authors:  Paul A Locke; Michael M Weil
Journal:  Front Oncol       Date:  2016-02-22       Impact factor: 6.244

9.  De novo assembly and characterization of breast cancer transcriptomes identifies large numbers of novel fusion-gene transcripts of potential functional significance.

Authors:  Vinay K Mittal; John F McDonald
Journal:  BMC Med Genomics       Date:  2017-08-29       Impact factor: 3.063

Review 10.  Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.

Authors:  Simona Soverini; Manuela Mancini; Luana Bavaro; Michele Cavo; Giovanni Martinelli
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.